Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2(V617F) cells

The JAK/STAT pathway is constitutively activated in myeloproliferative neoplasms and can be inhibited by ruxolitinib, a selective JAK1/2 inhibitor. The JAK2(V617F) mutation leads to constitutive STAT3 phosphorylation and potentially leads to inhibition of Stathmin 1 activity via STAT3. In support of...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget
Main Authors: Machado-Neto, João Agostinho, de Melo Campos, Paula, Favaro, Patricia, Lazarini, Mariana, da Silva Santos Duarte, Adriana, Lorand-Metze, Irene, Costa, Fernando Ferreira, Olalla Saad, Sara Teresinha, Traina, Fabiola
Format: Artigo
Language:Inglês
Published: Impact Journals LLC 2015
Subjects:
Research Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4745747/
https://ncbi.nlm.nih.gov/pubmed/26356819
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items